Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers

MolDX covers MRD testing (including NGS-based ClonoSeq®) for specified hematologic malignancies — ALL, MM, CLL, DLBCL, and mantle cell lymphoma — and allows single-gene PCR MRD tests (e.g., BCR-ABL1) per national/society guideline schedules. Billing requires DEX® registration and submission of the assigned DEX Z-Code® with one unit of service per episode or date of service, with NGS MRD testing generally limited to once per patient per cancer diagnosis and no more than once per month unless test-specific validity indicates otherwise.

"ClonoSeq® MRD testing is covered for patients with cancer diagnosed with acute lymphoblastic leukemia (ALL)."

Sign up to see full coverage criteria, indications, and limitations.